Factor

Outlook on the Protein Therapeutics Global Market to 2026 - by Product, Therapy Area, Function and Region - ResearchAndMarkets.com

Retrieved on: 
Monday, October 18, 2021
Biotechnology, Other Health, Health, Genetics, Pharmaceutical, Prevalence, Protein engineering, Diabetes, Peptide, Industry, Awareness, Lists of diseases, Cancer, Growth, Degenerative disease, Protein, Factor, Fibrinogen, Insulin, DARPin, Erythropoietin, Coronavirus, HGH, Neurodegeneration, A-DNA, Molecular Partners, Research, Drug discovery, COVID-19, R, Pharmaceutical industry, Vaccine, Fine chemical, Potash

Various combination therapy drugs are also used with protein therapeutics that can be inhaled, injected or orally administered.

Key Points: 
  • Various combination therapy drugs are also used with protein therapeutics that can be inhaled, injected or orally administered.
  • The increasing prevalence of chronic medical ailments is one of the key factors driving the growth of the protein therapeutics market.
  • How has the global protein therapeutics market performed so far and how will it perform in the coming years?
  • What is the structure of the global protein therapeutics market and who are the key players?

DGAP-News: Defence Therapeutics Inc.: DEFENCE THERAPEUTICS ACCUMTM VARIANTS IN VITRO STUDY INCREASES THE POTENCY OF T-DERUXTECAN ADC BY 5-FOLD ON BREAST CANCER

Retrieved on: 
Wednesday, October 13, 2021
Company, Forward-looking statement, DGAP, Therapy, USD, Trastuzumab, CSE, Engineering, CAGR, Breast cancer, Cell, Protein, Control, Growth, Cancer, ADC, FDA, Factor, Daiichi Sankyo, Infection, Vaccine, News, CEO, Catastrophic illness, AstraZeneca, Technology, HER2, Security (finance), Pharmaceutical industry, Fine chemical

Defence has successfully selected and tested 5 AccumTM variants to the T-deruxtecan ADC Therapeutic.

Key Points: 
  • Defence has successfully selected and tested 5 AccumTM variants to the T-deruxtecan ADC Therapeutic.
  • The 5 selected Accum-T-deruxtecan increases the potency of T-deruxtecan ADC Therapeutic by approximatively 5-fold on the HER2 positive breast cancer Trastuzumab and T-DM1 resistant cell line model named JIMT-1.
  • The 5 selected AccumTM variants will be sent to our collaborator at the HUS Comprehensive Cancer Center in Helsinki, Finland for the optimization of Defence's Accum-T-deruxtecan ADC Therapeutic.
  • Defence Therapeutics is a publicly-traded biotechnology company working on engineering the next generation vaccines and ADC products using its proprietary platform.

Gemini Therapeutics Announces Corporate Restructuring to Prioritize Late-Stage Clinical Development of GEM103 for Geographic Atrophy

Retrieved on: 
Tuesday, October 5, 2021
Health, Genetics, Other Health, General Health, Clinical Trials, Research, Science, People, U.S. Securities and Exchange Commission, Social media, Therapy, Geographic atrophy, Securities Act of 1933, Partnership, Sustainability Accounting Standards Board, Pharmacokinetics, Annual report, Boat, AMD, Patient, CFH, SEC, LinkedIn, Biomarker, Complement factor I, Board, Controller, CFI, Twitter, Company, Complement, Risk, Praecilia gens, COVID-19, Research, Forward-looking statement, Safety, File, Nasdaq, Anetoderma, GA, Factor, Pharmaceutical industry, Public relations, Management

Therefore, we are shifting Geminis focus from a research and development organization to exclusively become a development-stage company.

Key Points: 
  • Therefore, we are shifting Geminis focus from a research and development organization to exclusively become a development-stage company.
  • Gemini will concentrate its resources to advance GEM103 for the treatment of genetically defined age-related macular degeneration (AMD).
  • Gemini Therapeutics is a clinical stage precision medicine company developing novel therapeutic compounds to treat genetically defined age-related macular degeneration (AMD).
  • Gemini is also working to advance a potentiating antibody for CFH, GEM307, towards clinical development for treatment of systemic diseases.

Cerus Corporation Applauds FDA Requirements Effective Today to Safeguard the U.S. Platelet Supply

Retrieved on: 
Friday, October 1, 2021
General Health, FDA, Medical Devices, Health, Pharmaceutical, Irish Blood Transfusion Service, Food, Safety, Bleeding, Transfusion-associated graft-versus-host disease, Compliance, Standard of care, Transfusion, Factor, Health, FDA, Patient, Centers for Disease Control and Prevention, Parasitism, LinkedIn, Hospital, Virus, Bacteria, Vertically transmitted infection, CERS, Risk, Availability, Center, Transfusion medicine, CE, United, Cryoprecipitate, Industry, Plasma, Vaccine, Blood product, Medical device

Today marks the effective date for the U.S. Food and Drug Administrations (FDA) final guidance document on bacterial risk control strategies for platelet collection and transfusion.

Key Points: 
  • Today marks the effective date for the U.S. Food and Drug Administrations (FDA) final guidance document on bacterial risk control strategies for platelet collection and transfusion.
  • For two decades, the INTERCEPT Blood System for platelets and plasma has been used around the world to help safeguard the supply of platelets and plasma.
  • Today, Cerus INTERCEPT Blood System for platelets is the only FDA-approved pathogen reduction measure currently available in the U.S. for compliance with the FDA guidance.
  • INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.

Cerus Corporation Announces INTERCEPT Fibrinogen Complex Customer Presentations at SABM Virtual Annual Meeting 2021

Retrieved on: 
Monday, September 20, 2021
Medical Devices, FDA, Health, Hospitals, General Health, Pharmaceutical, Food, Assistant, Centers for Medicare & Medicaid Services, Bleeding, Factor, Regulation of tobacco by the U.S. Food and Drug Administration, Fibrinogen, Health, Irish Blood Transfusion Service, FDA, HCPCS, Medicare, Patient, CMS, Therapy, Master of Science, LinkedIn, Hospital, Corporation, CERS, NTAP, HCPCS Level 2, Society, Plasma, CE, Kaiser Permanente, Safety, Doctor of Philosophy, Nasdaq, Cryoprecipitate, Industry, Department, Online shopping, Pharmaceutical industry

Cerus Corporation (Nasdaq: CERS) today announced its participation in the Society for the Advancement of Blood Management (SABM) Virtual Annual Meeting, which is scheduled for September 22-25, 2021.

Key Points: 
  • Cerus Corporation (Nasdaq: CERS) today announced its participation in the Society for the Advancement of Blood Management (SABM) Virtual Annual Meeting, which is scheduled for September 22-25, 2021.
  • On Thursday, September 23, Cerus will host an industry workshop, Clinical need for and experience with the new Pathogen Reduced Cryoprecipitated Fibrinogen Complex (INTERCEPT Fibrinogen Complex), from 1:00-1:30p.m.
  • Cerus received approval from the U.S. Food and Drug Administration (FDA) in November 2020 for the INTERCEPT Blood System for Cryoprecipitation, which is used to produce INTERCEPT Fibrinogen Complex as well as Pathogen Reduced Plasma, Cryoprecipitate Reduced.
  • INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.

Cerus Corporation to Present at the 2021 Cantor Global Virtual Healthcare Conference

Retrieved on: 
Wednesday, September 15, 2021
General Health, Pharmaceutical, Health, Medical Supplies, Corporation, FDA, Conference, Plasma, Patient, Nasdaq, CE, LinkedIn, Bleeding, Factor, CERS, Webcast, Hospital, Cryoprecipitate, Medical device

Cerus Corporation (Nasdaq: CERS) today announced that William Obi Greenman, Cerus president and chief executive officer, and Kevin D. Green, Cerus chief financial officer, are scheduled to participate in the 2021 Cantor Global Virtual Healthcare Conference on Wednesday, September 29, 2021 at 11:20 a.m.

Key Points: 
  • Cerus Corporation (Nasdaq: CERS) today announced that William Obi Greenman, Cerus president and chief executive officer, and Kevin D. Green, Cerus chief financial officer, are scheduled to participate in the 2021 Cantor Global Virtual Healthcare Conference on Wednesday, September 29, 2021 at 11:20 a.m.
  • A live webcast of the presentation will be available on Cerus Investor Relations page at http://www.cerus.com/ir.
  • Cerus Corporation is dedicated solely to safeguarding the worlds blood supply and aims to become the preeminent global blood products company.
  • INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.

Magnet Forensics Acquires DME Forensics, a Leading Video and Multimedia Evidence Solution Company

Retrieved on: 
Monday, September 13, 2021
Public Policy, Government, Law Enforcement, Emergency Services, Security, Technology, Audio, Video, Software, Homeland Security, Magnet, Chicago Police Department, Achievement, Computer, Forward-looking statement, IOT, Ontario Securities Commission, Child, DVR, Safety, DVR-MS, Association, Solution, International Association of Chiefs of Police, Growth, Multimedia, Terrorism, Homicide, News, Digital, International Association, Factor, Crime, DME, Acquisition, MAGT, TSX, Police, Metadata, Mobile phone, Audit, Public Policy, Government, Law Enforcement, Emergency Services, Security, Technology, Audio, Video, Software, Homeland Security

Magnet Forensics Inc. (Magnet Forensics) (TSX:MAGT) a developer of digital investigation software used globally by public safety organizations and enterprises, today announced that it has acquired DME Forensics Inc. (DME), a video and multimedia evidence solution company.

Key Points: 
  • Magnet Forensics Inc. (Magnet Forensics) (TSX:MAGT) a developer of digital investigation software used globally by public safety organizations and enterprises, today announced that it has acquired DME Forensics Inc. (DME), a video and multimedia evidence solution company.
  • DMEs DVR Examiner enables investigators to recover video and metadata evidence from digital video recorder systems (DVRs) in a forensically sound manner.
  • Consolidating video evidence with other data types is an important component of Magnet Forensics vision, said Adam Belsher, chief executive officer of Magnet Forensics.
  • The video forensics capabilities of DME further strengthen and broaden our platform in this growth segment of digital investigations.

Gemini Therapeutics Announces Presentation of Previously Released Data from Its Ongoing Phase 2a Study of GEM103 at EURETINA 2021 Virtual

Retrieved on: 
Thursday, September 9, 2021
Biotechnology, Health, Genetics, Optical, Clinical Trials, the Phase 2a ReGAtta Study, GEM103, Dry Age-Related Macular Degeneration (AMD), Gemini Therapeutics, THE PHASE 2A REGATTA STUDY, GEM103, DRY AGE-RELATED MACULAR DEGENERATION (AMD), GEMINI THERAPEUTICS

The ReGAtta study is an open-label, single-arm dose escalation study of GEM103 in genetically-defined patients with geographic atrophy (GA) secondary to dry AMD.

Key Points: 
  • The ReGAtta study is an open-label, single-arm dose escalation study of GEM103 in genetically-defined patients with geographic atrophy (GA) secondary to dry AMD.
  • Summarized observations from the ongoing Phase 2a ReGAtta study, as of May 2021, presented at EURETINA 2021 include the following:
    For the 62 patients with GA enrolled, no systemic serious adverse events related to GEM103 were observed as of the May 2021 snapshot.
  • Information on Gemini Therapeutics, including GEM103 and initial ReGAtta data, and presentations made at EURETINA 2021 Virtual are available on Gemini Therapeutics website under the Investors & Media section: Events and Presentations.
  • Gemini Therapeutics is a clinical stage precision medicine company developing novel therapeutic compounds to treat genetically defined age-related macular degeneration (AMD).

Gemini Therapeutics Announces Presentation of Previously Released Data from Its Ongoing Phase 2a Study of GEM103 at Clinical Trials at the Summit

Retrieved on: 
Monday, August 30, 2021
Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, AMD, Population, Ageing, Retina, Twitter, Drug Quality and Security Act, Smoking, U.S. Securities and Exchange Commission, IVT, Night vision, SEC, PK, Social media, Geographic atrophy, Biomarker, Factor, Severe cognitive impairment, Nasdaq, Western world, Food, Disease, Therapy, Clinical trial, Regulation of tobacco by the U.S. Food and Drug Administration, CNV, Forward-looking statement, CFH, Investor, Securities Act of 1933, File, Reading, Safety, Risk, Intravitreal injection, Summit, Patient, Visual acuity, LinkedIn, CTS, Eye, Oxygen toxicity, A-DNA, FDA, Boat, Annual report, COVID-19, Anetoderma, Medical device, Risk management, Pharmaceutical industry, Medical imaging, Dietary supplement, Vaccine, the Phase 2a ReGAtta Study, GEM103, Dry Age-Related Macular Degeneration (AMD), Gemini Therapeutics, THE PHASE 2A REGATTA STUDY, GEM103, DRY AGE-RELATED MACULAR DEGENERATION (AMD), GEMINI THERAPEUTICS

We were pleased to have the opportunity to present at the Clinical Trials at the Summit to further discuss our initial data released from our Phase 2a ReGAtta study of GEM103 in patients with GA secondary to dry AMD, said Dr. Barone.

Key Points: 
  • We were pleased to have the opportunity to present at the Clinical Trials at the Summit to further discuss our initial data released from our Phase 2a ReGAtta study of GEM103 in patients with GA secondary to dry AMD, said Dr. Barone.
  • The current ongoing Phase 2a study is open-label, uncontrolled, and was not designed to detect statistically significant treatment effect.
  • Additional 26 patients were enrolled in a second cohort and received three monthly doses of 500g of GEM103 intravitreally.
  • Gemini Therapeutics is a clinical stage precision medicine company developing novel therapeutic compounds to treat genetically defined age-related macular degeneration (AMD).

Gemini Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update

Retrieved on: 
Thursday, August 12, 2021
Biotechnology, General Health, Health, Pharmaceutical, Clinical Trials, SEC, Poster, CFH, Smoking, Annual general meeting, Ageing, Anetoderma, 40, Population, GA, PK, FDA, Association, Safety, Boat, Choroidal neovascularization, U.S. Securities and Exchange Commission, CNV, Reading, Food, Geographic atrophy, LinkedIn, Securities Act of 1933, Night vision, AMD, Drug Quality and Security Act, Company, A-DNA, Research, Risk, Inflammation, Biomarker, Severe cognitive impairment, Regulation of tobacco by the U.S. Food and Drug Administration, Eye, MA, Retina, File, Annual report, Forward-looking statement, NAMD, Twitter, COVID-19, Disease, ARVO, Therapy, Patient, Pharmacokinetics, Nasdaq, Western world, Social media, Visual acuity, C3a, Factor, Pharmaceutical industry, Vaccine, the Phase 2a ReGAtta Study, the Phase 2a Study of Repeat Intravitreal Injections of GEM103 in Neovascular Age-related Macular Degeneration (nAMD), GEM103, Dry Age-Related Macular Degeneration (AMD), Gemini Therapeutics, THE PHASE 2A REGATTA STUDY, THE PHASE 2A STUDY OF REPEAT INTRAVITREAL INJECTIONS OF GEM103 IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD), GEM103, DRY AGE-RELATED MACULAR DEGENERATION (AMD), GEMINI THERAPEUTICS

Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today reported its financial results for the second quarter ended June 30, 2021 and provided a business update.

Key Points: 
  • Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today reported its financial results for the second quarter ended June 30, 2021 and provided a business update.
  • In May 2021, the Company completed enrollment in the Phase 2a safety and tolerability study.
  • At June 30, 2021, Gemini held $167.5 million in cash, $7.9 million of principal outstanding debt and 43.1 million shares outstanding.
  • Gemini Therapeutics is a clinical stage precision medicine company developing novel therapeutic compounds to treat genetically defined age-related macular degeneration (AMD).